BrdU
IHC, IP, IC
Wirt: Schaf
Polyclonal
unconjugated
Applikationshinweise
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Bromodeoxyuridine / BrdU antibody to be titered up or down for optimal performance. For staining of formalin-fixed tissues, incubate sections in 4N HCl for 30 minutes at RT followed by digestion with trypsin at 1 mg/mL PBS, 10 min at 37oC. 2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. IHC (FFPE): 0.5-1 μg/mL for 30 minutes at RT
Beschränkungen
Nur für Forschungszwecke einsetzbar
Buffer
0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store the BrdU antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
Target
BrdU
(Bromodeoxyuridine (BrdU))
Andere Bezeichnung
BrdU
Substanzklasse
Chemical
Hintergrund
This antibody reacts with Bromodeoxyuridine (BrdU) in single stranded DNA (produced by partial denaturation of double stranded DNA), BrdU coupled to a protein carrier, as well as free BrdU. BrdU is a thymidine analog, incorporated into cell nuclei during DNA synthesis prior to mitosis. Antibody to Bromodeoxyuridine / BrdU is helpful in detecting S-phase cells, providing useful information on the aggressiveness of tumors.